

Learn about common and serious side effects of Ortho Tri-Cyclen 28 Day, how to manage them, and when you should call your doctor right away.
Ortho Tri-Cyclen 28 Day (Norgestimate/Ethinyl Estradiol) is a triphasic combination birth control pill that's been used by millions of women. Like all hormonal contraceptives, it comes with potential side effects — most of them mild and temporary, but some that require immediate medical attention. This guide breaks down exactly what to expect and what to watch for.
Ortho Tri-Cyclen 28 Day is a combination oral contraceptive containing two hormones: the progestin Norgestimate and the estrogen Ethinyl Estradiol (0.035 mg). It's called "triphasic" because the Norgestimate dose changes across three phases during the 21 active pill days, while the estrogen dose stays the same. The brand has been discontinued, but identical generics like Tri-Sprintec, Tri-Estarylla, and Tri-Previfem are widely available. For more on what Ortho Tri-Cyclen is and how it works, see our detailed guide.
Most side effects of Ortho Tri-Cyclen 28 Day are mild and often improve within the first 2–3 months of use. These are reported in clinical trials and FDA labeling:
While rare, Ortho Tri-Cyclen 28 Day carries risks of serious side effects that require immediate medical attention. Call your doctor or go to the emergency room if you experience:
Ortho Tri-Cyclen 28 Day carries an FDA black box warning: Cigarette smoking increases the risk of serious cardiovascular events (blood clots, heart attack, stroke) from combination oral contraceptive use. This risk increases with age and number of cigarettes smoked. Women over 35 who smoke should not use this medication.
Ortho Tri-Cyclen is contraindicated during pregnancy. If you become pregnant while taking it, stop immediately and contact your doctor. It is not recommended during breastfeeding because estrogens pass into breast milk and may reduce milk production.
If you're over 35 and smoke, you should not take combination oral contraceptives. Non-smoking women over 35 can generally continue using them, but should discuss cardiovascular risk factors with their provider.
Ortho Tri-Cyclen is FDA-approved for acne treatment in females 15 and older who have reached menarche. Side effects in teens are similar to those in adults.
If you experience migraines with aura (visual disturbances, numbness, or tingling before the headache), you should not use combination oral contraceptives. Migraines with aura plus COC use significantly increases stroke risk. Migraines without aura may be acceptable — discuss with your doctor.
Most mild side effects improve within the first 2–3 months. Here are strategies to manage them:
If any side effect is persistent, bothersome, or worsening, don't stop your pill abruptly — talk to your doctor first. They may recommend switching to a different pill, such as a lower-dose or monophasic alternative.
Ortho Tri-Cyclen 28 Day is generally well-tolerated, and most side effects are mild and temporary. The triphasic design — with gradually increasing progestin doses — was created to mimic the body's natural hormone patterns, which some women find causes fewer side effects than monophasic pills.
The most important thing is to be aware of the serious warning signs (blood clots, stroke, severe headache with vision changes) and seek emergency care if they occur. For everything else, give your body 2–3 months to adjust before making a decision about switching.
If you're currently taking Ortho Tri-Cyclen and need help finding your generic in stock, Medfinder can help you check pharmacy availability near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.